Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds
The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein–protein interactions. We have refined crystallization conditions for KRAS169 Q61H-yielding crystals suitable for soaking wit...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 116; no. 7; pp. 2545 - 2550 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
12.02.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein–protein interactions. We have refined crystallization conditions for KRAS169
Q61H-yielding crystals suitable for soaking with compounds and exploited this to assess new RAS-binding compounds selected by screening a protein–protein interaction-focused compound library using surface plasmon resonance. Two compounds, referred to as PPIN-1 and PPIN-2, with related structures from 30 initial RAS binders showed binding to a pocket where compounds had been previously developed, including RAS effector protein–protein interaction inhibitors selected using an intracellular antibody fragment (called Abd compounds). Unlike the Abd series of RAS binders, PPIN-1 and PPIN-2 compounds were not competed by the inhibitory anti-RAS intracellular antibody fragment and did not show any RAS-effector inhibition properties. By fusing the common, anchoring part from the two new compounds with the inhibitory substituents of the Abd series, we have created a set of compounds that inhibit RAS-effector interactions with increased potency. These fused compounds add to the growing catalog of RAS protein–protein inhibitors and show that building a chemical series by crossing over two chemical series is a strategy to create RAS-binding small molecules. |
---|---|
AbstractList | The RAS family of oncogenic proteins is important as therapy targets because of the frequency of activating mutations in almost all major cancers. An important approach is development of small molecules with drug-like properties that can inhibit RAS-effector protein interactions inside cells. We present a strategy for identification of such compounds, and their development as RAS-effector interaction inhibitors, utilizing a structure-based design approach and cell-based assays. By combining moieties from two distinct sets of RAS-binding molecules, we generated cross-over compounds that showed improved efficacy in vitro and in cell-based assays.
The
RAS
gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein–protein interactions. We have refined crystallization conditions for KRAS
169
Q61H
-yielding crystals suitable for soaking with compounds and exploited this to assess new RAS-binding compounds selected by screening a protein–protein interaction-focused compound library using surface plasmon resonance. Two compounds, referred to as PPIN-1 and PPIN-2, with related structures from 30 initial RAS binders showed binding to a pocket where compounds had been previously developed, including RAS effector protein–protein interaction inhibitors selected using an intracellular antibody fragment (called Abd compounds). Unlike the Abd series of RAS binders, PPIN-1 and PPIN-2 compounds were not competed by the inhibitory anti-RAS intracellular antibody fragment and did not show any RAS-effector inhibition properties. By fusing the common, anchoring part from the two new compounds with the inhibitory substituents of the Abd series, we have created a set of compounds that inhibit RAS-effector interactions with increased potency. These fused compounds add to the growing catalog of RAS protein–protein inhibitors and show that building a chemical series by crossing over two chemical series is a strategy to create RAS-binding small molecules. The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein–protein interactions. We have refined crystallization conditions for KRAS169 Q61H-yielding crystals suitable for soaking with compounds and exploited this to assess new RAS-binding compounds selected by screening a protein–protein interaction-focused compound library using surface plasmon resonance. Two compounds, referred to as PPIN-1 and PPIN-2, with related structures from 30 initial RAS binders showed binding to a pocket where compounds had been previously developed, including RAS effector protein–protein interaction inhibitors selected using an intracellular antibody fragment (called Abd compounds). Unlike the Abd series of RAS binders, PPIN-1 and PPIN-2 compounds were not competed by the inhibitory anti-RAS intracellular antibody fragment and did not show any RAS-effector inhibition properties. By fusing the common, anchoring part from the two new compounds with the inhibitory substituents of the Abd series, we have created a set of compounds that inhibit RAS-effector interactions with increased potency. These fused compounds add to the growing catalog of RAS protein–protein inhibitors and show that building a chemical series by crossing over two chemical series is a strategy to create RAS-binding small molecules. The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein–protein interactions. We have refined crystallization conditions for KRAS 169 Q61H -yielding crystals suitable for soaking with compounds and exploited this to assess new RAS-binding compounds selected by screening a protein–protein interaction-focused compound library using surface plasmon resonance. Two compounds, referred to as PPIN-1 and PPIN-2, with related structures from 30 initial RAS binders showed binding to a pocket where compounds had been previously developed, including RAS effector protein–protein interaction inhibitors selected using an intracellular antibody fragment (called Abd compounds). Unlike the Abd series of RAS binders, PPIN-1 and PPIN-2 compounds were not competed by the inhibitory anti-RAS intracellular antibody fragment and did not show any RAS-effector inhibition properties. By fusing the common, anchoring part from the two new compounds with the inhibitory substituents of the Abd series, we have created a set of compounds that inhibit RAS-effector interactions with increased potency. These fused compounds add to the growing catalog of RAS protein–protein inhibitors and show that building a chemical series by crossing over two chemical series is a strategy to create RAS-binding small molecules. The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein–protein interactions. We have refined crystallization conditions for KRAS169Q61H-yielding crystals suitable for soaking with compounds and exploited this to assess new RAS-binding compounds selected by screening a protein–protein interaction-focused compound library using surface plasmon resonance. Two compounds, referred to as PPIN-1 and PPIN-2, with related structures from 30 initial RAS binders showed binding to a pocket where compounds had been previously developed, including RAS effector protein–protein interaction inhibitors selected using an intracellular antibody fragment (called Abd compounds). Unlike the Abd series of RAS binders, PPIN-1 and PPIN-2 compounds were not competed by the inhibitory anti-RAS intracellular antibody fragment and did not show any RAS-effector inhibition properties. By fusing the common, anchoring part from the two new compounds with the inhibitory substituents of the Abd series, we have created a set of compounds that inhibit RAS-effector interactions with increased potency. These fused compounds add to the growing catalog of RAS protein–protein inhibitors and show that building a chemical series by crossing over two chemical series is a strategy to create RAS-binding small molecules. The gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein-protein interactions. We have refined crystallization conditions for KRAS -yielding crystals suitable for soaking with compounds and exploited this to assess new RAS-binding compounds selected by screening a protein-protein interaction-focused compound library using surface plasmon resonance. Two compounds, referred to as PPIN-1 and PPIN-2, with related structures from 30 initial RAS binders showed binding to a pocket where compounds had been previously developed, including RAS effector protein-protein interaction inhibitors selected using an intracellular antibody fragment (called Abd compounds). Unlike the Abd series of RAS binders, PPIN-1 and PPIN-2 compounds were not competed by the inhibitory anti-RAS intracellular antibody fragment and did not show any RAS-effector inhibition properties. By fusing the common, anchoring part from the two new compounds with the inhibitory substituents of the Abd series, we have created a set of compounds that inhibit RAS-effector interactions with increased potency. These fused compounds add to the growing catalog of RAS protein-protein inhibitors and show that building a chemical series by crossing over two chemical series is a strategy to create RAS-binding small molecules. |
Author | Miller, Ami Phillips, Simon E. V. Carr, Stephen B. Bataille, Carole J. R. Bery, Nicolas Canning, Peter Russell, Angela J. Cruz-Migoni, Abimael Quevedo, Camilo E. Rabbitts, Terence H. |
Author_xml | – sequence: 1 givenname: Abimael surname: Cruz-Migoni fullname: Cruz-Migoni, Abimael – sequence: 2 givenname: Peter surname: Canning fullname: Canning, Peter – sequence: 3 givenname: Camilo E. surname: Quevedo fullname: Quevedo, Camilo E. – sequence: 4 givenname: Carole J. R. surname: Bataille fullname: Bataille, Carole J. R. – sequence: 5 givenname: Nicolas surname: Bery fullname: Bery, Nicolas – sequence: 6 givenname: Ami surname: Miller fullname: Miller, Ami – sequence: 7 givenname: Angela J. surname: Russell fullname: Russell, Angela J. – sequence: 8 givenname: Simon E. V. surname: Phillips fullname: Phillips, Simon E. V. – sequence: 9 givenname: Stephen B. surname: Carr fullname: Carr, Stephen B. – sequence: 10 givenname: Terence H. surname: Rabbitts fullname: Rabbitts, Terence H. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30683716$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkUtv1DAURi1URKeFNStQJDZs0l47GT82SFXFS6qERGFtOfZN61FiD3YyFfx6HGYYHivbuud-8qdzRk5CDEjIcwoXFERzuQ0mX1BJacOBUv6IrCgoWvNWwQlZATBRy5a1p-Qs5w0AqLWEJ-S0AS4bQfmK_Lid0mynOWHdmYyucrjDIW5HDFMV-yrgQ_X56rbGvkc7xVT5cO87X2656lMcK1PZOHY-mMnHsGwYO_kdVia4wh4eS0JhnA93C76Nc3D5KXncmyHjs8N5Tr6-e_vl-kN98-n9x-urm9quQU21U53rDEDXCDAohRUGnXTr1nZOMcPAstZSLqySSknLseMMcG17DtYoaZpz8mafu527EZ0tzZIZ9Db50aTvOhqv_50Ef6_v4k7zRoiW8xLw-hCQ4rcZ86RHny0OgwkY56wZFaplTMKCvvoP3cQ5hVLvF8UFQNsW6nJP2RRzTtgfP0NBL1714lX_8Vo2Xv7d4cj_FlmAF3tgk4ub45xxLplqaPMT2U-tKg |
CitedBy_id | crossref_primary_10_1002_cmdc_202200392 crossref_primary_10_1002_ange_202008361 crossref_primary_10_3390_cimb45030137 crossref_primary_10_1021_acs_jcim_3c00097 crossref_primary_10_1016_j_bpj_2022_04_026 crossref_primary_10_1016_j_cobme_2023_100455 crossref_primary_10_1016_j_jmb_2019_07_025 crossref_primary_10_1038_s41467_021_26526_y crossref_primary_10_1039_C9SC04726C crossref_primary_10_1021_acs_jmedchem_0c00511 crossref_primary_10_1042_BCJ20190839 crossref_primary_10_1080_21541248_2019_1655883 crossref_primary_10_1111_bph_15420 crossref_primary_10_3390_molecules28072886 crossref_primary_10_1016_j_jim_2021_113051 crossref_primary_10_1371_journal_pone_0253760 crossref_primary_10_1002_chem_201902810 crossref_primary_10_3389_fcell_2020_00240 crossref_primary_10_3390_molecules29102317 crossref_primary_10_1038_s41467_020_17022_w crossref_primary_10_1007_s11030_023_10777_6 crossref_primary_10_1016_j_isci_2024_109576 crossref_primary_10_1039_C9CC05122H crossref_primary_10_3390_pr9010071 crossref_primary_10_1016_j_bpj_2022_07_005 crossref_primary_10_1021_acs_jcim_3c01212 crossref_primary_10_1016_j_csbj_2019_12_004 crossref_primary_10_1038_s41368_022_00168_2 crossref_primary_10_7240_jeps_528662 crossref_primary_10_1038_s41392_023_01441_4 crossref_primary_10_1080_07391102_2023_2213355 crossref_primary_10_1016_j_tips_2024_03_005 crossref_primary_10_1021_acs_jpclett_0c00858 crossref_primary_10_3390_ijms222212142 crossref_primary_10_3390_antib12010024 crossref_primary_10_1016_j_compbiolchem_2023_107835 crossref_primary_10_3390_cancers13112541 crossref_primary_10_1016_j_path_2022_09_007 crossref_primary_10_1186_s12885_022_10236_9 crossref_primary_10_7554_eLife_76595 crossref_primary_10_1007_s00204_023_03471_x crossref_primary_10_1002_bies_202300088 crossref_primary_10_1016_j_ctrv_2020_101978 crossref_primary_10_1042_BST20201059 crossref_primary_10_1002_cmdc_202100167 crossref_primary_10_1515_hsz_2019_0330 crossref_primary_10_3390_ijms21010141 crossref_primary_10_1021_acs_jcim_2c01479 crossref_primary_10_1107_S2053230X20009012 crossref_primary_10_3389_fonc_2021_780655 crossref_primary_10_1016_j_chembiol_2020_12_012 crossref_primary_10_3390_cryst10090725 crossref_primary_10_1002_cbic_202300827 crossref_primary_10_1016_j_jmb_2022_167527 crossref_primary_10_2174_1568026620666200903163044 crossref_primary_10_1016_j_compbiomed_2021_104597 crossref_primary_10_1016_j_jmb_2021_166838 crossref_primary_10_1038_s41573_020_0068_6 crossref_primary_10_1002_anie_202008361 crossref_primary_10_1021_acsbiomedchemau_2c00045 crossref_primary_10_1073_pnas_1904529116 crossref_primary_10_3389_fonc_2021_768022 crossref_primary_10_1007_s40259_020_00419_w crossref_primary_10_1038_s41467_021_24316_0 crossref_primary_10_1007_s10555_020_09914_6 crossref_primary_10_1158_2767_9764_CRC_23_0222 crossref_primary_10_1021_acs_jpcb_1c01184 crossref_primary_10_1016_j_bpj_2019_12_039 crossref_primary_10_1038_s41598_021_81262_z crossref_primary_10_1080_07391102_2024_2331627 crossref_primary_10_1002_med_21863 crossref_primary_10_1007_s10858_020_00338_6 crossref_primary_10_3389_pore_2021_631095 crossref_primary_10_3390_cancers16101808 crossref_primary_10_1021_acs_jmedchem_0c01312 crossref_primary_10_3390_ijms24087373 crossref_primary_10_1158_0008_5472_CAN_22_0804 crossref_primary_10_1371_journal_pone_0219436 crossref_primary_10_1021_acs_jpcb_0c02642 crossref_primary_10_1021_acs_jcim_0c01470 crossref_primary_10_1146_annurev_med_080819_033145 crossref_primary_10_3390_ijms23073706 crossref_primary_10_1002_chem_202400304 crossref_primary_10_1038_s41598_023_28756_0 crossref_primary_10_1016_j_redox_2019_101282 crossref_primary_10_1038_s41467_019_10419_2 crossref_primary_10_2174_1381612828666220506144046 crossref_primary_10_3390_cancers15143579 crossref_primary_10_1016_j_annonc_2023_04_514 |
Cites_doi | 10.1016/0092-8674(92)90076-O 10.1073/pnas.1116510109 10.1038/520278a 10.1002/anie.201201358 10.1021/acs.jmedchem.5b01871 10.1371/journal.pone.0025711 10.1126/science.aad6204 10.1038/nature12796 10.7554/eLife.37122 10.1107/S0907444998012645 10.1074/jbc.272.22.14459 10.1016/j.jmb.2007.11.085 10.1038/s41467-018-05707-2 10.1016/j.cell.2016.03.045 10.1158/1541-7786.MCR-15-0203 10.1002/j.1460-2075.1989.tb03478.x 10.1021/acs.jmedchem.7b01120 10.1073/pnas.1521251113 10.1038/nchembio.1560 10.1038/nrd.2016.139 10.1016/S0968-0004(96)10064-5 10.1016/j.bmcl.2017.03.084 10.7554/eLife.31098 10.1007/978-1-61779-968-6_10 10.1021/jm501660t 10.1038/nrd.2016.29 10.1158/2159-8290.CD-15-1105 10.1038/nrc.2017.93 10.1016/j.cell.2017.02.006 10.1158/0008-5472.CAN-11-2612 10.1016/j.cell.2017.06.009 10.1038/nrd4389 10.1038/srep03643 10.1038/nrd.2016.268 10.1016/j.cell.2007.05.018 10.1152/physrev.00003.2012 10.1073/pnas.1315798111 |
ContentType | Journal Article |
Copyright | Copyright © 2019 the Author(s). Published by PNAS. Copyright National Academy of Sciences Feb 12, 2019 Copyright © 2019 the Author(s). Published by PNAS. 2019 |
Copyright_xml | – notice: Copyright © 2019 the Author(s). Published by PNAS. – notice: Copyright National Academy of Sciences Feb 12, 2019 – notice: Copyright © 2019 the Author(s). Published by PNAS. 2019 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QG 7QL 7QP 7QR 7SN 7SS 7T5 7TK 7TM 7TO 7U9 8FD C1K FR3 H94 M7N P64 RC3 7X8 5PM |
DOI | 10.1073/pnas.1811360116 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Nucleic Acids Abstracts Ecology Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Entomology Abstracts Genetics Abstracts Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Chemoreception Abstracts Immunology Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitleList | CrossRef Virology and AIDS Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Sciences (General) |
EISSN | 1091-6490 |
EndPage | 2550 |
ExternalDocumentID | 10_1073_pnas_1811360116 30683716 26682931 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Wellcome Trust – fundername: Wellcome Trust grantid: 099246/Z/12/Z – fundername: Wellcome Trust grantid: 100842/Z/12/Z – fundername: Medical Research Council grantid: MR/J000612/1 – fundername: wellcome trust grantid: 099246/Z/12/Z) – fundername: Medical Reseacrh Council grantid: MR/J000612/1 |
GroupedDBID | --- -DZ -~X .55 0R~ 123 29P 2AX 2FS 2WC 4.4 53G 5RE 5VS 85S AACGO AAFWJ AANCE ABBHK ABOCM ABPLY ABPPZ ABTLG ABXSQ ABZEH ACGOD ACIWK ACNCT ACPRK ADACV ADULT AENEX AEUPB AEXZC AFFNX AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS AQVQM BKOMP CS3 D0L DCCCD DIK DOOOF DU5 E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE IPSME JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JSODD JST KQ8 L7B LU7 N9A N~3 O9- OK1 PNE PQQKQ R.V RHF RHI RNA RNS RPM RXW SA0 SJN TAE TN5 UKR VQA W8F WH7 WOQ WOW X7M XSW Y6R YBH YKV YSK ZCA ~02 ~KM CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QG 7QL 7QP 7QR 7SN 7SS 7T5 7TK 7TM 7TO 7U9 8FD C1K FR3 H94 M7N P64 RC3 7X8 5PM |
ID | FETCH-LOGICAL-c509t-d9bdba00b370ae87c7aed8d54cbd92a20c24c167c98998c6eb620e5cf60ca98a3 |
IEDL.DBID | RPM |
ISSN | 0027-8424 |
IngestDate | Tue Sep 17 21:03:19 EDT 2024 Fri Oct 25 00:12:20 EDT 2024 Thu Oct 10 15:50:12 EDT 2024 Fri Dec 06 02:51:07 EST 2024 Sat Sep 28 08:30:07 EDT 2024 Tue Dec 10 23:54:46 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | cancer antibody RAS drugs intracellular antibody |
Language | English |
License | Copyright © 2019 the Author(s). Published by PNAS. This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c509t-d9bdba00b370ae87c7aed8d54cbd92a20c24c167c98998c6eb620e5cf60ca98a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 2Present address: Assay Development, LifeArc, Open Innovation Campus, SG1 2FX Stevenage, United Kingdom. 1A.C.-M., P.C., and C.E.Q. contributed equally to this work. Edited by James A. Wells, University of California, San Francisco, CA, and approved December 17, 2018 (received for review July 6, 2018) Author contributions: C.E.Q. and T.H.R. designed research; A.C.-M., P.C., C.J.R.B., N.B., and A.M. performed research; A.C.-M., P.C., C.E.Q., C.J.R.B., N.B., A.M., A.J.R., S.E.V.P., S.B.C., and T.H.R. analyzed data; and A.C.-M., P.C., C.E.Q., C.J.R.B., N.B., A.M., S.E.V.P., S.B.C., and T.H.R. wrote the paper. |
ORCID | 0000-0002-2643-3897 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377466/ |
PMID | 30683716 |
PQID | 2179670044 |
PQPubID | 42026 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6377466 proquest_miscellaneous_2179422806 proquest_journals_2179670044 crossref_primary_10_1073_pnas_1811360116 pubmed_primary_30683716 jstor_primary_26682931 |
PublicationCentury | 2000 |
PublicationDate | 2019-02-12 |
PublicationDateYYYYMMDD | 2019-02-12 |
PublicationDate_xml | – month: 02 year: 2019 text: 2019-02-12 day: 12 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Washington |
PublicationTitle | Proceedings of the National Academy of Sciences - PNAS |
PublicationTitleAlternate | Proc Natl Acad Sci U S A |
PublicationYear | 2019 |
Publisher | National Academy of Sciences |
Publisher_xml | – sequence: 0 name: National Academy of Sciences – name: National Academy of Sciences |
References | Grant BJ (e_1_3_4_29_2) 2011; 6 Quevedo CE (e_1_3_4_28_2) 2018; 9 Cruickshank DWJ (e_1_3_4_35_2) 1999; 55 Spiegel J (e_1_3_4_11_2) 2014; 10 Johnstone S (e_1_3_4_32_2) 2017; 27 Lawson ADG (e_1_3_4_33_2) 2018; 61 Wittinghofer A (e_1_3_4_5_2) 1996; 21 Maurer T (e_1_3_4_21_2) 2012; 109 Prior IA (e_1_3_4_2_2) 2012; 72 Ledford H (e_1_3_4_18_2) 2015; 520 Welsch ME (e_1_3_4_27_2) 2017; 168 Hunter JC (e_1_3_4_8_2) 2015; 13 e_1_3_4_41_2 e_1_3_4_40_2 Whyte DB (e_1_3_4_12_2) 1997; 272 Winter JJ (e_1_3_4_24_2) 2015; 58 Ostrem JM (e_1_3_4_17_2) 2016; 15 Bery N (e_1_3_4_31_2) 2018; 7 e_1_3_4_45_2 Martinko AJ (e_1_3_4_38_2) 2018; 7 e_1_3_4_44_2 Lito P (e_1_3_4_20_2) 2016; 351 e_1_3_4_43_2 Cherfils J (e_1_3_4_7_2) 2013; 93 e_1_3_4_42_2 Sewell H (e_1_3_4_30_2) 2014; 4 e_1_3_4_47_2 Ostrem JM (e_1_3_4_22_2) 2013; 503 e_1_3_4_46_2 Gutierrez L (e_1_3_4_4_2) 1989; 8 Patricelli MP (e_1_3_4_26_2) 2016; 6 Town J (e_1_3_4_37_2) 2016; 113 Tanaka T (e_1_3_4_14_2) 2012; 911 Andersson V (e_1_3_4_34_2) 2016; 59 Cochet O (e_1_3_4_15_2) 1998; 58 Wood KW (e_1_3_4_9_2) 1992; 68 Burns MC (e_1_3_4_19_2) 2014; 111 Tanaka T (e_1_3_4_13_2) 2008; 376 Dewhirst MW (e_1_3_4_16_2) 2017; 17 Beck A (e_1_3_4_36_2) 2017; 16 Simanshu DK (e_1_3_4_3_2) 2017; 170 Bos JL (e_1_3_4_6_2) 2007; 129 Sun Q (e_1_3_4_23_2) 2012; 51 Athuluri-Divakar SK (e_1_3_4_25_2) 2016; 165 Scott DE (e_1_3_4_10_2) 2016; 15 Cox AD (e_1_3_4_1_2) 2014; 13 e_1_3_4_39_2 |
References_xml | – volume: 68 start-page: 1041 year: 1992 ident: e_1_3_4_9_2 article-title: Ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK publication-title: Cell doi: 10.1016/0092-8674(92)90076-O contributor: fullname: Wood KW – volume: 109 start-page: 5299 year: 2012 ident: e_1_3_4_21_2 article-title: Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1116510109 contributor: fullname: Maurer T – volume: 520 start-page: 278 year: 2015 ident: e_1_3_4_18_2 article-title: Cancer: The Ras renaissance publication-title: Nature doi: 10.1038/520278a contributor: fullname: Ledford H – volume: 51 start-page: 6140 year: 2012 ident: e_1_3_4_23_2 article-title: Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation publication-title: Angew Chem Int Ed Engl doi: 10.1002/anie.201201358 contributor: fullname: Sun Q – volume: 59 start-page: 6658 year: 2016 ident: e_1_3_4_34_2 article-title: Macrocyclic prodrugs of a selective nonpeptidic direct thrombin inhibitor display high permeability, efficient bioconversion but low bioavailability publication-title: J Med Chem doi: 10.1021/acs.jmedchem.5b01871 contributor: fullname: Andersson V – volume: 6 start-page: e25711 year: 2011 ident: e_1_3_4_29_2 article-title: Novel allosteric sites on Ras for lead generation publication-title: PLoS One doi: 10.1371/journal.pone.0025711 contributor: fullname: Grant BJ – volume: 351 start-page: 604 year: 2016 ident: e_1_3_4_20_2 article-title: Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism publication-title: Science doi: 10.1126/science.aad6204 contributor: fullname: Lito P – volume: 503 start-page: 548 year: 2013 ident: e_1_3_4_22_2 article-title: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions publication-title: Nature doi: 10.1038/nature12796 contributor: fullname: Ostrem JM – volume: 7 start-page: e37122 year: 2018 ident: e_1_3_4_31_2 article-title: BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions publication-title: eLife doi: 10.7554/eLife.37122 contributor: fullname: Bery N – volume: 55 start-page: 583 year: 1999 ident: e_1_3_4_35_2 article-title: Remarks about protein structure precision publication-title: Acta Crystallogr D Biol Crystallogr doi: 10.1107/S0907444998012645 contributor: fullname: Cruickshank DWJ – ident: e_1_3_4_42_2 – volume: 272 start-page: 14459 year: 1997 ident: e_1_3_4_12_2 article-title: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors publication-title: J Biol Chem doi: 10.1074/jbc.272.22.14459 contributor: fullname: Whyte DB – volume: 376 start-page: 749 year: 2008 ident: e_1_3_4_13_2 article-title: Functional intracellular antibody fragments do not require invariant intra-domain disulfide bonds publication-title: J Mol Biol doi: 10.1016/j.jmb.2007.11.085 contributor: fullname: Tanaka T – volume: 9 start-page: 3169 year: 2018 ident: e_1_3_4_28_2 article-title: Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment publication-title: Nat Commun doi: 10.1038/s41467-018-05707-2 contributor: fullname: Quevedo CE – volume: 165 start-page: 643 year: 2016 ident: e_1_3_4_25_2 article-title: A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling publication-title: Cell doi: 10.1016/j.cell.2016.03.045 contributor: fullname: Athuluri-Divakar SK – ident: e_1_3_4_45_2 – volume: 13 start-page: 1325 year: 2015 ident: e_1_3_4_8_2 article-title: Biochemical and structural analysis of common cancer-associated KRAS mutations publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-15-0203 contributor: fullname: Hunter JC – volume: 8 start-page: 1093 year: 1989 ident: e_1_3_4_4_2 article-title: Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis publication-title: EMBO J doi: 10.1002/j.1460-2075.1989.tb03478.x contributor: fullname: Gutierrez L – volume: 58 start-page: 1170 year: 1998 ident: e_1_3_4_15_2 article-title: Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression publication-title: Cancer Res contributor: fullname: Cochet O – ident: e_1_3_4_44_2 – ident: e_1_3_4_47_2 – ident: e_1_3_4_41_2 – volume: 61 start-page: 4283 year: 2018 ident: e_1_3_4_33_2 article-title: Importance of rigidity in designing small molecule drugs to tackle protein-protein interactions (PPIs) through stabilization of desired conformers publication-title: J Med Chem doi: 10.1021/acs.jmedchem.7b01120 contributor: fullname: Lawson ADG – ident: e_1_3_4_39_2 – volume: 113 start-page: 3603 year: 2016 ident: e_1_3_4_37_2 article-title: Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1521251113 contributor: fullname: Town J – volume: 10 start-page: 613 year: 2014 ident: e_1_3_4_11_2 article-title: Small-molecule modulation of Ras signaling publication-title: Nat Chem Biol doi: 10.1038/nchembio.1560 contributor: fullname: Spiegel J – volume: 15 start-page: 771 year: 2016 ident: e_1_3_4_17_2 article-title: Direct small-molecule inhibitors of KRAS: From structural insights to mechanism-based design publication-title: Nat Rev Drug Discov doi: 10.1038/nrd.2016.139 contributor: fullname: Ostrem JM – volume: 21 start-page: 488 year: 1996 ident: e_1_3_4_5_2 article-title: How Ras-related proteins talk to their effectors publication-title: Trends Biochem Sci doi: 10.1016/S0968-0004(96)10064-5 contributor: fullname: Wittinghofer A – volume: 27 start-page: 2239 year: 2017 ident: e_1_3_4_32_2 article-title: Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective publication-title: Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2017.03.084 contributor: fullname: Johnstone S – volume: 7 start-page: e31098 year: 2018 ident: e_1_3_4_38_2 article-title: Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins publication-title: eLife doi: 10.7554/eLife.31098 contributor: fullname: Martinko AJ – volume: 911 start-page: 151 year: 2012 ident: e_1_3_4_14_2 article-title: Intracellular antibody capture (IAC) methods for single domain antibodies publication-title: Methods Mol Biol doi: 10.1007/978-1-61779-968-6_10 contributor: fullname: Tanaka T – volume: 58 start-page: 2265 year: 2015 ident: e_1_3_4_24_2 article-title: Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation publication-title: J Med Chem doi: 10.1021/jm501660t contributor: fullname: Winter JJ – volume: 15 start-page: 533 year: 2016 ident: e_1_3_4_10_2 article-title: Small molecules, big targets: Drug discovery faces the protein-protein interaction challenge publication-title: Nat Rev Drug Discov doi: 10.1038/nrd.2016.29 contributor: fullname: Scott DE – volume: 6 start-page: 316 year: 2016 ident: e_1_3_4_26_2 article-title: Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-15-1105 contributor: fullname: Patricelli MP – volume: 17 start-page: 738 year: 2017 ident: e_1_3_4_16_2 article-title: Transport of drugs from blood vessels to tumour tissue publication-title: Nat Rev Cancer doi: 10.1038/nrc.2017.93 contributor: fullname: Dewhirst MW – ident: e_1_3_4_40_2 – volume: 168 start-page: 878 year: 2017 ident: e_1_3_4_27_2 article-title: Multivalent small-molecule Pan-RAS inhibitors publication-title: Cell doi: 10.1016/j.cell.2017.02.006 contributor: fullname: Welsch ME – volume: 72 start-page: 2457 year: 2012 ident: e_1_3_4_2_2 article-title: A comprehensive survey of Ras mutations in cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-11-2612 contributor: fullname: Prior IA – ident: e_1_3_4_43_2 – volume: 170 start-page: 17 year: 2017 ident: e_1_3_4_3_2 article-title: RAS proteins and their regulators in human disease publication-title: Cell doi: 10.1016/j.cell.2017.06.009 contributor: fullname: Simanshu DK – volume: 13 start-page: 828 year: 2014 ident: e_1_3_4_1_2 article-title: Drugging the undruggable RAS: Mission possible? publication-title: Nat Rev Drug Discov doi: 10.1038/nrd4389 contributor: fullname: Cox AD – volume: 4 start-page: 3643 year: 2014 ident: e_1_3_4_30_2 article-title: Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex publication-title: Sci Rep doi: 10.1038/srep03643 contributor: fullname: Sewell H – volume: 16 start-page: 315 year: 2017 ident: e_1_3_4_36_2 article-title: Strategies and challenges for the next generation of antibody-drug conjugates publication-title: Nat Rev Drug Discov doi: 10.1038/nrd.2016.268 contributor: fullname: Beck A – ident: e_1_3_4_46_2 – volume: 129 start-page: 865 year: 2007 ident: e_1_3_4_6_2 article-title: GEFs and GAPs: Critical elements in the control of small G proteins publication-title: Cell doi: 10.1016/j.cell.2007.05.018 contributor: fullname: Bos JL – volume: 93 start-page: 269 year: 2013 ident: e_1_3_4_7_2 article-title: Regulation of small GTPases by GEFs, GAPs, and GDIs publication-title: Physiol Rev doi: 10.1152/physrev.00003.2012 contributor: fullname: Cherfils J – volume: 111 start-page: 3401 year: 2014 ident: e_1_3_4_19_2 article-title: Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1315798111 contributor: fullname: Burns MC |
SSID | ssj0009580 |
Score | 2.618177 |
Snippet | The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for... The gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for... The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for... The RAS family of oncogenic proteins is important as therapy targets because of the frequency of activating mutations in almost all major cancers. An important... |
SourceID | pubmedcentral proquest crossref pubmed jstor |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 2545 |
SubjectTerms | Anchoring Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Binders Binding Biological Sciences Crystallization Crystallography, X-Ray Crystals Drug Development Inhibitors Intracellular Molecular Structure Oncogene Protein p21(ras) - antagonists & inhibitors Oncogene Protein p21(ras) - metabolism Organic chemistry Protein Binding Protein interaction Proteins Ras protein Surface Plasmon Resonance |
Title | Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds |
URI | https://www.jstor.org/stable/26682931 https://www.ncbi.nlm.nih.gov/pubmed/30683716 https://www.proquest.com/docview/2179670044 https://search.proquest.com/docview/2179422806 https://pubmed.ncbi.nlm.nih.gov/PMC6377466 |
Volume | 116 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NaxUxEB_aHqQXsWp1tZYIHuoh7-3bZJPNsRRLESpiLfS25OvRBZv36Gsv_vXOZD_aiiePSyYh7G-S-Q2ZD4BPrkG1UcZyxLvhUorATW0c91bbsgxRCEPZyOff1Nml_HpVX21BPebC5KB977pZ-nUzS911jq1c3_j5GCc2_35-ogSSFqXm27CN5nd00adKu02fd1Lh9SsrOdbz0WK-TnYzQ5O2EIreH3bhGe4TPTRqdv7IKvWBif-inH9HTj4yRacv4PnAIdlxv9c92IrpJewNp3TDjoZS0p9fwe-LXB72_jZyMleBhYcYIbZaMuTU7MfxBe-jOla3rEvXneuoAw-jxBNmGWokOs8ZP5ph8_3IbAooO3zQCq7L6TEkvqZOTZvXcHn65efJGR-6LXCPpOGOB-OCQ3yc0KWNjfbaxtCEWnoXTGWr0lfSL5T2hlw0r6JTVRlrv1Slt6axYh920irFt8BiEKYRCn-yx4vYLaxW1kqxRO4Qkb6pAo7Gv92u-6IabX4M16IljNoHjArYz2hMckgoGqQoiwIORnja4dhtWvSvDOUdSVnAx2kYDwy9gtgUV_e9DNU9K3HtNz2a0-KjOhSgn-A8CVAx7qcjqKO5KPegk-_-e-Z72EUyZnhuNnMAO6gf8QMSnjt3SOamPsxq_gdp7AFn |
link.rule.ids | 230,314,727,780,784,885,27924,27925,53791,53793 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTxQxFH9BTJSLERUcRa2JBzx0d2baaadHQiSrssQIJNwm_dowiXQ3LFz8633tfADGk8dJX5tmfq99v5e-D4BPpka1EUpTxLumnDNHVaUMtVrqPHeeMRWzkecnYnbOv11UFxtQDbkwKWjfmnYSfl1NQnuZYitXV3Y6xIlNf8wPBUPSIsT0ETyumFTF4KSPtXbrLvOkxAuYl3yo6CPZdBX0eoJGrWAivkBswRPcKfposd35PbvUhSb-i3T-HTt5zxgdPYdnPYskB91ut2HDhxew3Z_TNdnvi0l_fgm_T1OB2NtrT6PBcsTdRQmR5YIgqyY_D05pF9exvCZtuGxNG3vwkJh6QjRBnUT3OSEYZ-h0QxIdHMr2H3EF06YEmSi-ir2a1q_g_OjL2eGM9v0WqEXacEOdMs4gQobJXPtaWqm9q13FrXGq1GVuS24LIa2KTpoV3ogy95VdiNxqVWu2A5thGfxrIN4xVTOBP9niVWwKLYXWnC2QPXgkcCKD_eFvN6uurEaTnsMlayJGzR1GGewkNEY5pBQ1kpQig70BnqY_eOsGPSwVM484z-DjOIxHJr6D6OCXt51MrHyW49q7HZrj4oM6ZCAf4DwKxHLcD0dQS1NZ7l4r3_z3zA_wdHY2P26Ov558fwtbSM0UTa1n9mATdcW_Q_pzY94nZf8DBa8D1g |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RkBCXqtDSpqWtK_VAD95kY8eJj4h2BW1BqBSJW-TXikjFG7Fw4dczdh4sVU89Rh5bVr6x5xt5HgCfdYVqI6SiiHdFOWeWykJqalSpssw6xmTIRj45FUcX_PtlcbnS6isG7RvdTPyf64lvrmJsZXtt0iFOLD07ORQMSYsQaWvn6TPYKBgq2eCoj_V2qy77JMdLmOd8qOpTsrT1ajlBwzZlIrxCbMEm7hb9tNDyfMU2deGJ_yKef8dPrhik2Qt43jNJctDteBvWnN-B7f6sLsl-X1D6y0u4P49FYu9uHA1GyxL7GClEFnOCzJr8OjinXWzH4oY0_qrRTejDQ0L6CVEE9RJd6IhimKHiLUmUtyjbf4QVdBOTZIJ4G_o1LV_Bxezb78Mj2vdcoAapwy21UluNKGlWZspVpSmVs5UtuNFW5irPTM7NVJRGBkfNCKdFnrnCzEVmlKwU24V1v_DuDRBnmayYwJ9s8DrWU1UKpTibI4NwSOJEAvvD367brrRGHZ_ES1YHjOpHjBLYjWiMckgrKiQq0wT2Bnjq_vAta_SyZMg-4jyBT-MwHpvwFqK8W9x1MqH6WYZrv-7QHBcf1CGB8gnOo0Aoyf10BDU1lubuNfPtf8_8CJtnX2f1z-PTH-9gC9mZpLH7zB6so6q498iAbvWHqOsPvwUE6Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Structure-based+development+of+new+RAS-effector+inhibitors+from+a+combination+of+active+and+inactive+RAS-binding+compounds&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Cruz-Migoni%2C+Abimael&rft.au=Canning%2C+Peter&rft.au=Quevedo%2C+Camilo+E&rft.au=R+Bataille%2C+Carole+J&rft.date=2019-02-12&rft.pub=National+Academy+of+Sciences&rft.issn=0027-8424&rft.eissn=1091-6490&rft.volume=116&rft.issue=7&rft.spage=2545&rft_id=info:doi/10.1073%2Fpnas.1811360116&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0027-8424&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0027-8424&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0027-8424&client=summon |